Cross Country Healthcare, Inc.
$13.25$0.00 (0.0%)
Last close · Data as of Jul 28, 2026
- Market cap
- $409.0M
- P/E
- -4.3x
- EV / EBITDA
- -4.7x
- Revenue
- $1.1B
- Net margin
- -9.0%
- ROCE
- -1.1%
Price chart
Technical chartScreen technicals →Hidden because the last close is more than three trading days older than the latest prices of its class.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 28 Jul 2026 close.
- 1M
- Stale
- 3M
- Stale
- 6M
- Stale
- 1Y
- Stale
- 5Y
- Stale
- Hidden because the last close is more than three trading days older than the latest prices of its class.
52-week range
Day change $0.00 (0.0%) from $13.25 to $13.25 · Last close Jul 28, 2026
Best weekday to invest, historically
The same weekly amount in CCRN, bought on each weekday since 2021.
News & filings
What Cross Country Healthcare filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 94.9 million US dollars in fiscal 2025.
Strengths (1)
- The company carries almost no debt: debt to equity of 0.01.
- Prices are as of 28 Jul 2026; price-based points are paused until newer prices arrive.
Prices to the 28 Jul 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Cross Country Healthcare, Inc. provides talent management services for healthcare clients in the United States. The company operates in two segments: Nurse and Allied Staffing, and Physician Staffing.
Read moreShow less
Cross Country Healthcare, Inc. provides talent management services for healthcare clients in the United States. The company operates in two segments: Nurse and Allied Staffing, and Physician Staffing. The Nurse and Allied Staffing segment provides traditional staffing, recruiting, and value-added total talent solutions, including temporary and permanent placement of travel nurse and allied professionals, per diem, and healthcare leaders within nursing, allied, human resources, and finance; vendor neutral and managed services programs; and education healthcare, caregiver services, and outsourcing services. This segment offers staffing solutions for registered nurses, licensed practical nurses, certified nurse assistants, practitioners, pharmacists, and other allied professionals on per diem and short-term assignments; and clinical and non-clinical professionals on long-term assignments, as well as workforce solutions, including MSP, VMS, RPO, project management, and other outsourcing and consultative services. It also provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. The company serves public and private acute care and non-acute care hospitals, government facilities, local and national healthcare plans, managed care providers, public and charter schools, outpatient clinics, ambulatory care facilities, correctional facilities, PACE programs, physician practice groups, and other healthcare providers. The Physician Staffing segment provides physicians in various specialties, certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments. This segment serves various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations. The company was founded in 1986 and is headquartered in Boca Raton, Florida.
- Sector
- Healthcare
- Shares outstanding
- 31.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $409.0M
- P/E
- -4.3x
- P/B
- 1.3x
- EV / EBITDA
- -4.7x
- EV / Sales
- 0.3x
- P/S
- 0.4x
- 52-week high
- $14.23
- 52-week low
- $7.53
Profitability
- Operating margin
- -0.4%
- Net margin
- -9.0%
- EBITDA margin
- -6.1%
- ROE
- -29.4%
- ROCE
- -1.1%
- ROIC
- -29.7%
- ROA
- -21.1%
- Asset turnover
- 2.35
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.1B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -21.6%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -27.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 551.6%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $40.1M
Solvency
- Current ratio
- 3.78
- Debt / Equity
- 0.01
- Debt / Assets
- 0.01
- CFO / Net profit
- -0.51
- Cash / Market cap
- 26.6%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $1.1B |
| Cost of revenue | $840.7M |
| Gross profit | $213.6M |
| Operating expenses | $217.5M |
| Selling, general and administrative | $200.7M |
| Operating income | -$3.9M |
| Interest and other | -$79.6M |
| Pretax income | -$83.5M |
| Tax and other | $11.3M |
| Net income | -$94.8M |
Revenue and net profit
Revenue fell 21.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $2.8B | $186.0M |
| FY2023 | $2.0B | $72.6M |
| FY2024 | $1.3B | -$14.6M |
| FY2025 | $1.1B | -$94.9M |
Cash flows
FY2025: $48.3M from operations, $40.1M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $134.1M | $125.3M |
| FY2023 | $248.5M | $234.5M |
| FY2024 | $120.1M | $111.4M |
| FY2025 | $48.3M | $40.1M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.1B-21.6%1Y
- EBITDA
- -$64.5M-1,716.5%1Y
- Net profit
- -$94.9M
- Cash from operations
- $48.3M-59.8%1Y
- Free cash flow
- $40.1M-64.0%1Y
- Revenue CAGR, 3Y
- -27.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.1B | -$64.5M | -$94.9M | $40.1M | -29.4% | -21.6% | +551.6% |
Monthly returns
Month-by-month returns of CCRN across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $448.9M |
| Current assets | $293.6M |
| Non-current assets | $155.4M |
| Liabilities | $126.1M |
| Current liabilities | $77.8M |
| Non-current liabilities | $48.4M |
| Equity | $322.8M |
| Paid-in capital | $201.2M |
| Retained earnings | $123.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; CCRN highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Monopar Therapeutics Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Cross Country Healthcare, Inc.CCRNthis company | $409.0M | -4.3x | 1.3x | -29.4% | -4.7x |
| ClearPoint Neuro, Inc.CLPT | $429.5M | -16.8x | 15.3x | -91.1% | -21.2x |
| Orthofix Medical Inc.OFIX | $418.0M | -4.5x | 0.9x | -20.5% | 51.8x |
| Upstream Bio, Inc.UPB | $404.3M | -2.8x | 1.2x | -42.2% | -1.9x |
| AirSculpt Technologies, Inc.AIRS | $402.8M | -34.5x | 4.6x | -13.3% | 391.4x |
| Monopar Therapeutics Inc.MNPR | $399.3M | -29.1x | 2.9x | -10.0% | -20.2x |
| Community Health Systems, Inc.CYH | $393.2M | 0.8x | -0.3x | -36.5% | 5.5x |
| TruBridge, Inc.TBRG | $390.7M | 89.7x | 2.2x | 2.4% | 12.5x |
| OmniAb, Inc.OABI | $385.6M | -6.0x | 1.4x | -24.3% | -8.1x |
| Peer median | — | -5.2x | 1.8x | -22.4% | 1.8x |
Year-to-date ROI
CCRN since 1 January, against earlier years.
Historical volatility
CCRN's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 10.3% |
| FY2023 | 6.5% |
| FY2024 | 1.7% |
| FY2025 | -0.4% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.1B |
| Cost of revenueCost Of Revenue | $840.7M |
| Gross profitGross Profit | $213.6M |
| Operating expensesOperating Expense | — |
| Selling, general and administrativeSelling General And Administration | $200.7M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $16.8M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $16.8M |
| Provision for doubtful accountsProvision For Doubtful Accounts | — |
| Total expensesTotal Expenses | $1.1B |
| Operating incomeOperating Income | -$3.9M |
| Interest and other | |
| Pretax incomePretax Income | -$83.5M |
| TaxTax Provision | $11.3M |
| Net incomeNet Income | -$94.8M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $448.9M |
| Current assetsCurrent Assets | $293.6M |
| Non-current assetsTotal Non Current Assets | $155.4M |
| LiabilitiesTotal Liabilities Net Minority Interest | $126.1M |
| Current liabilitiesCurrent Liabilities | $77.8M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $48.4M |
| EquityTotal Equity Gross Minority Interest | $322.8M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $48.3M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $48.3M |
| Net income, continuing operationsNet Income From Continuing Operations | -$94.8M |
| Depreciation and amortisationDepreciation And Amortization | $16.8M |
| Stock-based compensationStock Based Compensation | $7.1M |
| Deferred taxDeferred Tax | — |
| Deferred income taxDeferred Income Tax | $10.1M |
| Operating gains and lossesOperating Gains Losses | — |
| Asset impairmentAsset Impairment Charge | $77.8M |
| Provision and write off of assetsProvisionand Write Offof Assets | -$1.0M |
| Change in working capitalChange In Working Capital | $30.5M |
| Other non-cash itemsOther Non Cash Items | $1.8M |
| Investing cash flowInvesting Cash Flow | -$8.2M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$8.2M |
| Capital expenditureCapital Expenditure | -$8.2M |
| Purchase of PP&EPurchase Of PPE | -$8.2M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$8.2M |
| AcquisitionsPurchase Of Business | — |
| DisposalsSale Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Financing cash flowFinancing Cash Flow | -$13.0M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$13.0M |
| Debt issuedIssuance Of Debt | $1.4M |
| Debt repaidRepayment Of Debt | -$1.4M |
| Net debt issuedNet Issuance Payments Of Debt | $0.00 |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $1.4M |
| Long-term debt repaidLong Term Debt Payments | -$1.4M |
| Net long-term debt issuedNet Long Term Debt Issuance | $0.00 |
| Net common stock issuedNet Common Stock Issuance | -$6.8M |
| Common stock repurchasedCommon Stock Payments | -$6.8M |
| Share buybacksRepurchase Of Capital Stock | -$6.8M |
| Other financing chargesNet Other Financing Charges | -$6.2M |
| Change in cashChanges In Cash | $27.1M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 2.0% |
| Cash at the start of the yearBeginning Cash Position | $81.6M |
| Cash at the end of the yearEnd Cash Position | $108.7M |
| Free cash flowFree Cash Flow | $40.1M |
| Supplemental |
Learn while you research
Academy chapters picked for Cross Country Healthcare, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read